Few More Plays For Tuesday

[Vipyr]

GBN at 1.92
MMSV at 1.50
MSEV at 0.036
ISV at 1.60
also from earlier post  GCOG and WOLV

[joozt]

all in the green, well done!

[Vipyr]

MMSV gained 76.67% today.. hope some of you made bank here
MSEV gained 19% today... another bank play
GBN gained 0.52% was not the greatest, not even close
ISV gained 5.6%  not great, but playable.

Trying to get scans done for Wednesday

[buyhighsellow]

Aplaud!Vipyr!
Danks!
MMSV is really strong today!
But I got in 2 late ,@2.54
Hopefully tomorrow I don't have to buyhighsellow.

[buyhighsellow]

wonderfulday for msev!
aplaud!
I still hold my MMSV.
Hit 3.20 today,then pulls back slightly,but the volume is much smaller than yesterday's.
If it touch 5ma tomorrow,i'll double my positions @ .10 higher than 5MA.

[buyhighsellow]

I doubled my positions today @2.64.
MMSV : Close:2.70
Will go up again.

[fill_the_gap]

Hi,

Buying large percentage of portfolio into ISV right now.

The call should bode very well.

Looking for 30 cent move near term, imo.

[fill_the_gap]

Press Release Source: InSite Vision Incorporated


InSite Vision Reports Second Quarter 2007 Financial Results
Wednesday August 8, 4:05 pm ET


ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV - News), an ophthalmic therapeutics, diagnostics and drug delivery company, today reported financial results for the three months ended June 30, 2007.
Net income for the second quarter ended June 30, 2007 is $2.2 million, or $0.02 per share, compared to a net loss of $5.1 million or $ 0.06 per share for the second quarter 2006. The difference was attributed mainly to the recognition of deferred revenue related to the licensing of AzaSite(TM) (1% azithromycin ophthalmic solution) to Inspire Pharmaceuticals and the milestone payment, received following the signing of the agreement and approval of AzaSite(TM) by the FDA on April 27, 2007.

Research and development (R&D) expenses were $2.1 million for the second quarter 2007, compared to $2.8 million in the same quarter in 2006.

Selling, general and administrative (SG&A) expenses increased to $2.1 million in the second quarter 2007, compared to $1.7 million in the same quarter in 2006.

InSite Vision had cash and cash equivalents of $18.9 million at June 30, 2007, compared to $986,000 at December 31, 2006.

For the six months ended June 30, 2007, the Company reported a net loss of $416,000 or, $0.00 per share compared to a net loss of $10.5 million or $0.12 per share for the six months ended June 30, 2006.

Research and development expenses decreased to $3.9 million for the first six months of 2007, compared to $6.0 million in the first six months of 2006. This was due largely to a decrease in external service expenses, which had been primarily related to the AzaSite clinical trials, preparation of the related NDA and the filing fee in 2006.

Selling, general and administrative expenses increased to $3.7 million for the first six months of 2007 compared to $3.4 million in the first six months of 2006.

"With the approval and imminent launch of AzaSite(TM), InSite Vision is at a pivotal point in our business. By leveraging our DuraSite technology and the revenue from AzaSite commercialization, we believe that we have technological and financial capabilities to expand and advance our product pipeline and lead us to profitability and growth," said S. Kumar Chandrasekaran, PhD, chief executive officer, InSite Vision

[Stocky2000]

you find much better stocks out there in uptrend and much more volume...

[Allwaysright]

My picks NNSR has show a volume increase, a new strong base, ready for upward movement.

GCME great news, moving slowly but surely.

CYTV ready to move anytime.